Cabergoline is used in the treatment of prolactin-producing tumors. It is taken orally in the form of a tablet. It is usually given twice a week. This medication can cause dizziness. If you experience this side effect, it is important to get up slowly from a lying or sitting position.

1. What is Cabergoline?

Cabergoline is an anti-prolactin drug used to treat abnormally high levels of prolactin, a hormone that causes a number of symptoms in women and men. It works by mimicking the naturally occurring dopamine in the brain and binding to dopamine receptors, which signals the pituitary gland to reduce production of prolactin. This helps restore hormonal balance and alleviates symptoms associated with elevated prolactin, including irregular menstrual periods, difficulty conceiving, infertility, and excessive milk production in non-pregnant individuals. It is also a potent inhibitor of prolactin secretion in women during breastfeeding.

In adults, Cabergoline for Bodybuilding has been well tolerated with few side effects reported. It is a highly protein bound medication that does not cross the blood-brain barrier and is eliminated primarily via the kidneys. The pharmacokinetics of Cabergoline have not been affected by age or by food intake. Cabergoline is extensively metabolized in both animals and humans, mainly by hydrolysis of the acylurea bond or the urea moiety. It does not induce or inhibit the hepatic enzymes CYP2C19 and CYP3A4 in humans, although significant metabolism to a variety of metabolites occurs.

In some patients with mild to moderate hepatic dysfunction, the use of Cabergoline may increase the blood concentrations of the active drug and enhance the risk of adverse reactions. The pharmacokinetics of the medication has not been assessed in patients with severe liver or renal impairment. Cabergoline should be used with extreme caution in patients with a history of heart disease, as it can cause valvular problems (e.g., shortness of breath, ankle swelling) in some individuals.

2. How to Use Cabergoline

If you have been prescribed this medication, your health expert will determine the dosage and how often it is taken. You should follow your doctor’s orders exactly and ask about any other information that may be important to you. For example, if you are older than 65 years of age, your doctor may start you on a lower dose or adjust the frequency of the dosing. This is because your body may clear this medication more slowly, putting you at risk for side effects.

Depending on the individual, some symptoms that can occur when taking cabergoline include changes in appetite, dizziness, and nausea. You should let your family and friends know of these possible side effects. If these symptoms are severe, you should call your doctor immediately.

You should not take cabergoline if you are pregnant or breast-feeding. In addition, long-term treatment with this drug can cause psychiatric problems such as pathological gambling or increased libido. This can be very dangerous for you and your loved ones. You should tell your doctor if you have any psychiatric problems before starting treatment.

Some medications can interact with cabergoline, including antipsychotics and some antifungal drugs. You should also inform your doctor about any other prescription or non-prescription medications you are taking, including vitamins and herbal supplements.

3. Cabergoline Cycle: Vital Information for Optimal Results & Usage

Cabergoline is an effective and better-tolerated drug compared to the older bromocriptine for treatment of hyperprolactinemia in PCOS patients. In addition, it increases a luteinizing hormone and follicle - stimulating hormone level which helps in achieving successful IVF/ICSI cycles in these women.

However, the use of this medication should be restricted for the following reasons:

Severe allergic reactions to ergot derivatives, including cabergoline, have been reported. This includes bronchopulmonary symptoms such as asthma, pleural effusion and/or pulmonary fibrosis, gastrointestinal symptoms (including hepatitis) and psychiatric symptoms. Uncontrolled hypertension can also occur in patients taking this medicine.

Patients should not drive or engage in other activities requiring alertness while on this medication. Serious side effects from this drug can include dizziness and somnolence. Patients should be advised to avoid alcohol consumption while on this medication.

This medication should not be taken with erythromycin or clarithromycin, as these types of antibiotics increase the level of this medication in the blood. Similarly, patients should not take domperidone or metoclopramide (used to treat nausea/vomiting), as they counteract the effect of cabergoline.

Cabergoline should not be used during pregnancy or while breastfeeding. It is excreted into human milk and may cause adverse effects in infants. Women on long-term therapy should inform their doctor if they plan to become pregnant or breastfeed. This drug should be discontinued immediately if pregnancy is detected.

Read More Blog: Cabergoline How to Buy the Right Dose at the Best Price

4. Cabergoline Cycle: Vital Information for Optimal Results & Usage

Cabergoline is an ergot dopamine agonist that has proved effective for the treatment of hyperprolactinaemia idiopathic or due to pituitary adenomas. It has superior efficacy to bromocriptine and has a better compliance profile and fewer side effects. It has also been found to be a useful medication for the control of hyperprolactinaemia in patients undergoing IVF/ICSI cycles.

Long-term therapy with cabergoline should be avoided in women who are planning pregnancy, as it may result in fetal loss. It should be stopped one month before conception. The drug should not be co-administered with other ergot alkaloids or other medications that act by inhibiting dopamine uptake, such as clonidine, clonippine, methadone and phenytoin, as they may significantly decrease its absorption or affect its pharmacodynamic effects. It is also contraindicated in patients with severe cardiovascular disease, Raynaud’s syndrome, renal insufficiency, peptic ulcer or history of serious mental disorders.

Regular echocardiographic monitoring of aortic, mitral and tricuspid valves (and chest X-ray examination) should be carried out in patients receiving cabergoline for extended periods. If valvular regurgitation is detected, the dose should be reduced or the medication discontinued. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. Symptomatic hypotension can occur, so patients should be careful driving or operating machinery until such episodes and somnolence have resolved.